EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 390 filers reported holding EXELIXIS INC in Q3 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,502,668 | +12.8% | 68,772 | -1.4% | 0.02% | +11.1% |
| Q2 2023 | $1,332,655 | -3.5% | 69,736 | -2.0% | 0.02% | -10.0% |
| Q1 2023 | $1,380,905 | +21.9% | 71,144 | +0.7% | 0.02% | +11.1% |
| Q4 2022 | $1,132,777 | +11.8% | 70,622 | +9.3% | 0.02% | -5.3% |
| Q3 2022 | $1,013,000 | -25.2% | 64,612 | -0.7% | 0.02% | -29.6% |
| Q2 2022 | $1,355,000 | -2.7% | 65,095 | +5.9% | 0.03% | +17.4% |
| Q1 2022 | $1,393,000 | +21.9% | 61,457 | -1.7% | 0.02% | +27.8% |
| Q4 2021 | $1,143,000 | -13.0% | 62,510 | +0.6% | 0.02% | -28.0% |
| Q3 2021 | $1,314,000 | +13.8% | 62,151 | -1.9% | 0.02% | +19.0% |
| Q2 2021 | $1,155,000 | +15.8% | 63,379 | +43.6% | 0.02% | 0.0% |
| Q1 2021 | $997,000 | +12.8% | 44,150 | +0.3% | 0.02% | +10.5% |
| Q4 2020 | $884,000 | -17.3% | 44,021 | +0.7% | 0.02% | -26.9% |
| Q3 2020 | $1,069,000 | +15.9% | 43,717 | +12.6% | 0.03% | +8.3% |
| Q2 2020 | $922,000 | – | 38,833 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 15,001,073 | $265,294,000 | 64.62% |
| Sargent Investment Group, LLC | 465,620 | $8,234,000 | 3.70% |
| Orbimed Advisors | 3,912,900 | $69,200,000 | 1.31% |
| Bellevue Group AG | 3,858,700 | $68,241,000 | 1.27% |
| TEALWOOD ASSET MANAGEMENT INC | 137,129 | $2,425,000 | 1.04% |
| CAPITAL MANAGEMENT CORP /VA | 200,995 | $3,555,000 | 0.97% |
| Penn Capital Management Company, LLC | 517,988 | $9,161,000 | 0.96% |
| Chicago Capital, LLC | 801,560 | $14,176,000 | 0.95% |
| Portolan Capital Management | 454,444 | $8,037,000 | 0.91% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 103,534 | $1,830,000 | 0.85% |